Windtree Therapeutics (Nasdaq: WINT) Makes NASDAQ Top Gainers List on News of Istaroxime Clinical Development and Upcoming Clinical Trial Data

Windtree Therapeutics (Nasdaq: WINT) Makes NASDAQ Top Gainers List on News of Istaroxime Clinical Development and Upcoming Clinical Trial Data: Windtree Therapeutics (Nasdaq: WINT) Makes NASDAQ Top Gainers List on News of Istaroxime Clinical Development and Upcoming Clinical Trial Data

MIRA Pharmaceuticals (NASDAQ: MIRA) Stock Rallies; Investors High on News of preclinical study results for oral ketamine analog, Ketamir-2

MIRA Pharmaceuticals (NASDAQ: MIRA) Stock Rallies; Investors High on News of preclinical study results for oral ketamine analog, Ketamir-2: MIRA Pharmaceuticals (NASDAQ: MIRA) Stock Rallies; Investors High on News of preclinical study results for oral ketamine analog, Ketamir-2

New Stocks to watch in the Biotech and Cleantech Sectors; (TSXV: $YNV.V) (OTCQB: $YNVYF) (NASDAQ: $SLS) (NASDAQ: $SYRS) (NYSE: $LICY) (NASDAQ: $RDUS) (NASDAQ: $STLD) (NYSE: $LZM)

 New Stocks to watch in the Biotech and Cleantech Sectors; (TSXV:  $YNV.V) (OTCQB: $YNVYF) (NASDAQ: $SLS) (NASDAQ: $SYRS) (NYSE: $LICY) (NASDAQ: $RDUS) (NASDAQ: $STLD) (NYSE: $LZM)

 

 

 

 

July 19, 2024 – (Investorideas.com Newswire) Investorideas.com, a global news source and expert investing resource, announces today’s roundup of stocks to watch in the Biotech, Cleantech Sectors.

 

The newest biotech companies are involved in blood disorder treatments, cancer treatments and medical at home test e-papers.

 

The latest cleantech companies provide recycling services for batteries and metals.

 

Read this in full at https://www.investorideas.com/news/2024/main/07191Stocks.asp

 

Investor Ideas is always researching and searching for new stocks to add to our growing list of free stock directories. The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

 

New Stocks Added to the Biotech Directories:

Ynvisible Interactive Inc. (TSXV: YNV) (OTCQB: YNVYF) (FSE: 1XNA) is disrupting the low-cost and ultra-low-power display industry thanks to the latest advantages in sustainable electronics and roll-to-roll printing production. Ynvisible's printed e-paper displays are ideal for low-power and cost-sensitive applications, such as digital signage, smart monitoring labels, authenticity and security, and retail labels and signage. Ynvisible has the experience, know-how, and intellectual property in electrochromic materials, inks, and systems and offers a mix of services, materials, and technology to brand owners developing smart objects and IoT products. Biotech - Ynvisible to Deliver First E-paper Displays for Medical At-Home Tests

 

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. SELLAS’ other lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has the potential as a monotherapy and combination with other therapies to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is also developing SLS009 (formerly GFH009) - potentially the first and best-in-class differentiated small molecule CDK9 inhibitor with reduced toxicity and increased potency compared to other CDK9 inhibitors. Data suggests that SLS009 demonstrated a high response rate in AML patients with unfavorable prognostic factors including ASXL1 mutation, commonly associated with poor prognosis in various myeloid diseases.

 

Syros Pharmaceuticals (NASDAQ:SYRS) is committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies. Driven by the motivation to help patients with blood disorders that have largely eluded other targeted approaches, Syros is developing tamibarotene, an oral selective RARα agonist in frontline patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia with RARA gene overexpression.

 

New Stocks Added to the Cleantech Directories:

Li-Cycle Holdings Corp. (NYSE: LICY) is a leading global lithium-ion battery resource recovery company. Established in 2016, and with major customers and partners around the world, Li-Cycle’s mission is to recover critical battery-grade materials to create a domestic closed-loop battery supply chain for a clean energy future. The Company leverages its innovative, sustainable and patent-protected Spoke & Hub Technologies™ to recycle all different types of lithium-ion batteries. At our Spokes, or pre-processing facilities, we recycle battery manufacturing scrap and end-of-life batteries to produce black mass, a powder-like substance which contains a number of valuable metals, including lithium, nickel and cobalt. At our future Hubs, or post-processing facilities, we plan to process black mass to produce critical battery-grade materials, including lithium carbonate, for the lithium-ion battery supply chain.

 

Radius Recycling, Inc. (NASDAQ: RDUS) (formerly Schnitzer Steel Industries, Inc.) is one of the largest manufacturers and exporters of recycled metal products in North America with operating facilities located in 25 states, Puerto Rico, and Western Canada. Radius has seven deep water export facilities located on both the East and West Coasts and in Hawaii and Puerto Rico. The Company’s integrated operating platform also includes 50 stores which sell serviceable used auto parts from salvaged vehicles and receive over 4 million annual retail visits. The Company’s steel manufacturing operations produce finished steel products, including rebar, wire rod, and other specialty products. The Company began operations in 1906 in Portland, Oregon.

 

Steel Dynamics, Inc. (NASDAQ:STLD) is one of the largest domestic steel producers and metals recyclers in North America, based on estimated annual steelmaking and metals recycling capability, with facilities located throughout the United States, and in Mexico. Steel Dynamics produces steel products, including hot roll, cold roll, and coated sheet steel, structural steel beams and shapes, rail, engineered special-bar-quality steel, cold finished steel, merchant bar products, specialty steel sections, and steel joists and deck. In addition, the company produces liquid pig iron and processes and sells ferrous and nonferrous scrap.

 

Lifezone Metals (NYSE: LZM) mission is to provide cleaner and more responsible metals production and recycling. Using a scalable platform underpinned by our Hydromet Technology, we offer the potential for lower energy, lower emission and lower cost metals production compared to traditional smelting. Our Kabanga Nickel Project in Tanzania is believed to be one of the world's largest and highest-grade undeveloped nickel sulfide deposits. By pairing with our Hydromet Technology, we are working to unlock a new source of LME-grade nickel, copper and cobalt for the global battery metals markets, to empower Tanzania to achieve full in-country value creation and become the next premier source of Class 1 nickel. A Definitive Feasibility Study for the project is due for completion in Q3 2024. Through our US-based, platinum, palladium and rhodium recycling partnership, we are working to demonstrate that our Hydromet Technology can process and recover platinum group metals from responsibly sourced spent automotive catalytic converters in a cleaner and more efficient way than conventional smelting and refining methods.

 

About Investorideas.com - Big Investing Ideas

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for various sectors, including gaming, biotech, tech and sports. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors. Paid content is always disclosed.

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Learn more about our news, PR and social media, podcast and ticker tag services at Investorideas.com

https://www.investorideas.com/Investors/Services.asp

 

Learn more about advertising and guest posts

https://www.investorideas.com/Advertise/

 

Follow us on Twitter (X) https://X.com/Investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

 

Contact Investorideas.com to be added to our stock directories or learn more about us

Dawn Van Zant and Cali Van Zant

 

800 665 0411

 

 

 

 

Biotech/Pharma Stocks to Watch Citius Pharmaceuticals (Nasdaq: $CTXR), Soligenix (Nasdaq: $SNGX), Takeda (NYSE: $TAK), Pfizer (NASDAQ: $PFE)

 

Biotech/Pharma Stocks to Watch Citius Pharmaceuticals (Nasdaq: $CTXR), Soligenix (Nasdaq: $SNGX), Takeda (NYSE: $TAK), Pfizer (NASDAQ: $PFE)

 

The Race for Solutions for Cutaneous T-Cell Lymphoma (CTCL)

 

July 18, 2024 - Investorideas.com, a go-to investing platform releases the second of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. (Nasdaq:CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. The Company's diversified pipeline includes two late-stage product candidates.

 

Looking specifically at the opportunity for Cutaneous T-Cell Lymphoma (CTCL) treatments, the  market was approximately USD 399 Million in 2021 says Delveinsight. “CTCL has an active pipeline as many pharmaceutical companies are working toward developing an effective and affordable therapy. The disease has a tendency to show resistance to medications creating a need for a more efficacious and effective drug.”

 

The US Cutaneous T-cell Lymphoma Market is projected to reach $1.38 Billion by 2030 reports Insights10.

 

Citius Pharmaceuticals (Nasdaq:CTXR) is approaching the FDA target date of August 13^th for its LYMPHIR product candidate to address this unmet need.

 

Citius announced earlier this year that the US Food and Drug Administration (FDA) has accepted the resubmission of the Company's Biologics License Application (BLA) for LYMPHIR™ (denileukin diftitox), an IL-2-based immunotherapy for the treatment of patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy. The FDA has assigned a PDUFA goal date of August 13, 2024.

 

Paid news dissemination for Citius Pharmaceuticals.

 

Read this article featuring CTXR in full at https://www.investorideas.com/news/2024/biotech/07181Cutaneous-T-Cell-Lymphoma.asp

 

"The acceptance of the BLA resubmission reflects the completeness of our response to the enhanced product testing and additional controls highlighted by the FDA in their July 2023 CRL.  No concerns relating to safety or efficacy were noted in the letter, and we remain confident in the robustness of the clinical data package included with the initial BLA submission," stated Leonard Mazur, Chairman and CEO of Citius.

 

"We believe there remains a critical unmet need for an additional viable treatment option for patients with relapsed or refractory CTCL as current therapies are non-curative. We are grateful for the FDA's vital support for rare disease drug development as we work to expand treatment options for patients with cutaneous T-cell lymphoma. We look forward to the FDA's decision and the potential benefit LYMPHIR may provide patients with relapsed or refractory CTCL," added Mazur.

 

More from the news: The BLA is supported by a pivotal Phase 3 study (NCT01871727). The resubmission follows dialog with the FDA resulting from a Complete Response Letter (CRL) received on July 28, 2023. Citius believes it has addressed enhanced product testing and additional manufacturing controls noted in the letter. There were no safety or efficacy issues cited and no additional trials required.

 

EF Hutton just initiated coverage of Citius Pharmaceuticals (Nasdaq:CTXR) with a Buy recommendation with a price target of $6.00. Analyst Jason Kolbert sees the stock as low risk – high reward based on their two late stage therapeutics, Mino-Lok and LYMPHIR.

 

Talking about LYMPHIR he said, “Since CTCL treatments are non-curative and often have a limited duration of response and/or discontinued early, patients are put on multiple alternative therapies.

 

“LYMPHIR’s differentiated MOA reinforces rationale for inclusion among the current core therapeutic options in the US market.”

 

Kolbert also notes, “We assume a price of $200,000 per treatment, consistent with competing therapies in the CTCL space.”

 

Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, on July 9^th announced an interim update on the open-label, investigator-initiated study (IIS) evaluating extended HyBryte™ treatment for up to 12 months in patients with early-stage cutaneous T-cell lymphoma (CTCL). The trial is sponsored by Ellen Kim, MD, Director, Penn Cutaneous Lymphoma Program, Vice Chair of Clinical Operations, Dermatology Department, and Professor of Dermatology at the Hospital of the University of Pennsylvania who was a leading enroller in the Phase 3 FLASH (Fluorescent Light Activated Synthetic Hypericin) study for the treatment of early-stage CTCL. To date six patients have been enrolled and treated with HyBryte™ over a time period ranging up to 44 weeks. Patients have responded positively to HyBryte™ therapy with 75% (3 of the 4 subjects who have completed at least 12 weeks of therapy) already achieving "Treatment Success", as predefined in the study's protocol as ≥50% improvement in their cumulative mCAILS (modified Composite Assessment of Index Lesion Severity) score compared to Baseline. Of the three Treatment Successes, two were achieved within the first 12 weeks of treatment and the third within 18 weeks. Of the remaining three patients, two have only recently started HyBryte™ therapy and have not yet reached their first efficacy evaluation visit (i.e., at Week 6) and the other had a substantial improvement documented at the Week 18 visit, but has not yet achieved the success threshold. In addition, HyBryte™ appears to be safe and well tolerated in all patients, with no treatment-related adverse events reported to date.

 

Continued: "In the Phase 3 FLASH study, HyBryte™ was shown to be efficacious with a promising safety profile. With limited treatment options, especially in the early stages of their disease, CTCL patients are often searching for alternative treatments. In our U.S. Food and Drug Administration (FDA)-funded study, initial results evaluating the expanded use of HyBryte™ in a 'real world' treatment setting are promising, further supporting and extending results from the previous positive Phase 2 and 3 clinical trials," noted Dr. Kim, Principal Investigator of the IIS. "We look forward to continuing to work with the FDA to complete this study and to participating in the upcoming confirmatory Phase 3 placebo-controlled study."

 

In June, Takeda (NYSE: TAK) and Pfizer (NASDAQ: PFE) announced Four-Year results from positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma.

 

The four-year analysis presented by the GHSG showed superior progression-free survival (PFS) and improved tolerability for patients compared to a current standard of care regimen used in Europe in this setting.

 

“In our ongoing effort to improve outcomes for patients with lymphoma, we’ve partnered with the GHSG on the HD21 study to deepen our understanding of how ADCETRIS could further benefit patients in need of new options,” said Awny Farajallah, Chief Medical Officer, Global Oncology at Takeda.

 

The HD21 study is a Phase 3, randomized, multi-country, prospective, open-label study, sponsored by the GHSG and supported by Takeda, designed to evaluate ADCETRIS in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone (BrECADD) in comparison to a standard of care treatment – escalated doses of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone (eBEACOPP) – in patients with newly diagnosed Stage IIb/III/IV classical Hodgkin lymphoma. At a preplanned three-year analysis, the study met its co-primary endpoints, with the ADCETRIS combination regimen demonstrating significantly.

 

More from the news: ADCETRIS received conditional marketing authorization from the European Commission in October 2012, and the specific obligations of the conditional marketing authorization were fulfilled in May 2022. The approved indications in the European Union are: (1) for the treatment of adult patients with previously untreated CD30-positive Stage III & IV Hodgkin lymphoma in combination with doxorubicin, vinblastine and dacarbazine (AVD), (2) for the treatment of adult patients with CD30-positive Hodgkin lymphoma at increased risk of relapse or progression following ASCT, (3) for the treatment of adult patients with relapsed or refractory CD30-positive Hodgkin lymphoma following ASCT, or following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option, (4) for the treatment of adult patients with relapsed or refractory sALCL, (5) for the treatment of adult patients with previously untreated sALCL in combination with CHP and (6) for the treatment of adult patients with CD30-positive cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.

 

ADCETRIS has received marketing authorization by regulatory authorities in more than 70 countries for relapsed or refractory Hodgkin lymphoma and sALCL.

 

Continued: ADCETRIS is being evaluated broadly in more than 70 clinical trials, including a Phase 3 study in first-line Hodgkin lymphoma (ECHELON-1) and another Phase 3 study in first-line CD30-positive peripheral T-cell lymphomas (ECHELON-2), as well as trials in many additional types of CD30-positive malignancies.

 

Pfizer and Takeda fund joint development costs for ADCETRIS on a 50:50 basis, except in Japan where Takeda is solely responsible for development costs.

 

Citius Pharmaceuticals, Inc. (Nasdaq:CTXR) says on its website, “There is no single standard-of-care for the treatment of CTCL, with only a few FDA-approved targeted therapies for patients with advanced CTCL. Existing targeted therapies are often poorly tolerated or have limited efficacy and may be discontinued due to toxicity, adverse events, or the development of resistance to treatment. As such, we expect LYMPHIRTM, with its unique non-cross-resistant mechanism-of-action and ONTAK’s prior well documented safety and efficacy profile, to be an important option for patients and their physicians in the management of this disease.”

 

Read part one of this series - Analysts Hunt for Undervalued Biotech Stocks

https://www.investorideas.com/news/2024/biotech/07113Transformative-Biopharma-Stocks.asp

 

Research and find more biotech stocks at Investorideas.com

https://www.investorideas.com/BIS/Stock_List.asp

About Investorideas.com

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for sectors including mining, crypto, renewable energy, gaming, biotech, tech, sports and more.

 

Disclaimer/Disclosure: This news article featuring Citius Pharmaceuticals, Inc. (CTXR) a paid for news release creation and dissemination on Investorideas.com.  Our site does not make recommendations for purchases or sale of stocks, services or products.  This is not investment opinion: Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services and prices on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ Global investors must adhere to regulations of each country. Privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Follow us on X @investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

 

Contact Investorideas.com

800-665-0411

 

Biotech Industry Stocks- investing ideas in biotechnology stocks, medical technology and life sciences

Get more biotech and medical tech news, articles, podcasts and stock directories

Analysts Hunt for Undervalued Biotech Stocks - Citius Pharmaceuticals (NASDAQ: $CTXR) Jazz Pharmaceuticals (NASDAQ: $JAZZ) CRISPR (NASDAQ: $CRSP) Krystal Biotech (NASDAQ: $KRYS)

 

Analysts Hunt for Undervalued Biotech Stocks - Citius Pharmaceuticals (NASDAQ: $CTXR) Jazz Pharmaceuticals (NASDAQ: $JAZZ) CRISPR (NASDAQ: $CRSP) Krystal Biotech (NASDAQ: $KRYS)

 

July 17, 2024 - Investorideas.com, a go-to investing platform releases the first of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. The Company's diversified pipeline includes two late-stage product candidates.

 

Looking at the sector, Morningstar reported in June, “Biotech had a strong start to 2024, driven by an uptick in M&A and every indication that interest rates would begin to decline,” says Morningstar strategist Karen Andersen. “However, the second quarter has been more mixed for the industry, as rates look to be stabilizing rather than declining, given persistent (but improving) inflation. Higher rates tend to make waiting for uncertain returns on biotech investments less attractive.”

 

“We still see tailwinds for the industry going forward. Smaller-cap names are still targets for acquisitions by bigger biopharma firms, and a wave of acquisitions has continued since late last year, particularly focused on oncology and immunology,” she says. “We think obesity acquisitions are likely going forward, as big biopharma can bring development and commercialization expertise to multiple programs in midstage trials at small biotechs. Second, on a more fundamental level, new technologies and launches in new therapeutic areas are poised to boost productivity and drive biotech performance.”

 

This week, EF Hutton initiated coverage of Citius Pharmaceuticals (Nasdaq:CTXR) with a Buy recommendation with a price target of $6.00. Analyst Jason Kolbert sees the stock as low risk – high reward based on their two late stage therapeutics, Mino-Lok and LYMPHIR. He also notes that a planned IPO for LYMPHIR this summer, in addition to an early August PDUFA should be catalysts to unlock value for Citius.   

 

Paid news dissemination for Citius Pharmaceuticals.

 

Read this article, featuring CTXR in full at: https://www.investorideas.com/news/2024/biotech/07171Undervalued-Biotech-Stocks.asp

 

Mino-Lok (MLT), a novel antibiotic lock solution that combines minocycline, ethanol and edetate disodium, is designed to treat patients with catheter-related blood stream infections. Citius licensed Mino-Lok from an affiliate of The University of Texas MD Anderson Cancer Center. Mino-Lok is designed to offer an alternative to removing and replacing a central venous catheter (CVC), which may lead to a reduction in serious adverse events and cost savings to the healthcare system. If approved, Mino-Lok would be the first and only FDA-approved treatment that salvages central venous catheters that cause central line-related blood stream infections.

 

LYMPHIR is a recombinant fusion protein that combines the interleukin-2 (IL-2) receptor binding domain with diphtheria toxin fragments. The agent specifically binds to IL-2 receptors on the cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis. In 2011 and 2013, the FDA granted orphan drug designation to LYMPHIR for the treatment of PTCL and CTCL, respectively. In 2021, denileukin diftitox received regulatory approval in Japan for the treatment of CTCL and peripheral T-cell lymphoma (PTCL). Subsequently in 2021, Citius acquired an exclusive license with rights to develop and commercialize LYMPHIR in all markets except for Japan and certain parts of Asia.

 

In recent news from the company, Leonard Mazur, Chairman and CEO of Citius stated, "Our solid execution since the beginning of the year sets us up for potentially transformative catalysts in the coming months. Mino-Lok's strong Phase 3 topline results support its potential to become part of the standard of care for treating catheter-related bloodstream infections. Mino-Lok would also have a first and only advantage in a market with no approved or investigational products for salvaging infected central venous catheters. For LYMPHIR™, the FDA is currently reviewing our Biologics License Application, with an expected decision on August 13th. We are preparing for near-term commercialization of LYMPHIR if approved. These near-term catalysts should enable the company to optimize its current cash runway, future cash needs, as well as create potential non-dilutive cash opportunities.”

 

In its most recent update, the company also discussed the pending IPO, reporting, “Citius plans to merge a wholly owned subsidiary with TenX Keane Acquisition (Nasdaq:TENK) to form publicly listed company, Citius Oncology, Inc. The transaction is pending review by the U.S. Securities and Exchange Commission (SEC) and TENK shareholder approval as well as contractual and customary closing conditions.”

 

Looking at some of Morningstar’s top biotech picks, they report, “These were the most undervalued biotech stocks that Morningstar’s analysts cover as of June 5, 2024:  Intellia Therapeutics ,Crispr Therapeutics ,Royalty Pharma ,Jazz Pharmaceuticals, Moderna, Ionis Pharmaceuticals, and Incyte.

 

Jazz Pharmaceuticals (NASDAQ: JAZZ), with its diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments made their list with them saying, ”Jazz Pharmaceuticals is next on our list of affordable biotech stocks. Strong commercial launches for several products have continued to be Jazz’s primary growth driver. Jazz Pharmaceuticals looks undervalued as it trades 44% below our fair value estimate of $187 per share...”

 

CRISPR Therapeutics AG (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, say it is “Among our best biotech stocks to buy now, Crispr proved most resistant to the recent industry volatility. The company continues to possess a sizable, mostly early-stage pipeline, and it invests heavily in research and development.”

 

CRISPR also made the Insider Monkey top ten biotech stocks list, which noted, “CRISPR Therapeutics AG (NASDAQ: CRSP) is one of the more revolutionary medical companies since it is one of the few and one of the earliest players in the genetic sequencing industry. Estimates suggest that the market for CRISPR gene editing technologies can grow at a compounded annual growth rate of 22.3% between 2022 and 2027 to be worth an estimated $9.2 billion at the end of the forecast period. CRISPR Therapeutics AG's revenue was $370 million in 2023, leaving it with quite a bit of room to grow. Key to CRISPR Therapeutics AG's success though is the broader biotechnology industry's ability to commercialize treatments with its technology. These led to royalty payments, and one such payment came in Q1 from pharma giant Vertex Pharmaceuticals. Vertex's Casgevy is one of the few sickle cell disease treatments in the world, and its maker paid CRISPR Therapeutics AG $170 million in 2023 as a milestone payment. CRISPR Therapeutics AG, is eligible for another $130 million, and will also receive royalties from future treatments developed with its technology.”

 

For investors getting a sense of the rankings, According to IBD, “The industry group has a Relative Strength Rating of 83, which has improved from 74 just a week ago, according to IBD Digital. This means the industry group now ranks in the top 17% of all industry groups in terms of 12-month performance.”

 

On June 11^th, IBD reported, “Krystal Biotech (NASDAQ:KRYS) stock cleared an important technical benchmark, seeing its Relative Strength (RS) Rating jump into the 90-plus percentile with an improvement to 91, up from 88 the day before.”

 

On June 20^th, TimesSquare Capital Management, an equity investment management company, released its ‘US Small Cap Growth Strategy’ first-quarter 2024 investor letter. TimesSquare Capital US Small Cap Growth Strategy highlighted stocks like Krystal Biotech, Inc. (NASDAQ: KRYS), in the first quarter 2024 investor letter. Krystal Biotech, Inc. is a commercial-stage biotechnology company that develops genetic medicines for patients with rare diseases. The one-month return of Krystal Biotech was 5.15%, and its shares gained 43.27% of their value over the last 52 weeks. On June 20, 2024, the stock closed at $171.21 per share with a market capitalization of $4.889 billion.

 

Krystal Biotech joined the S&P 600 Index on June 24^th.

 

Biotech stocks took center stage during Covid and as the sector continues to reinvent the future of health, they are still on the must watch list for analysts searching for an undervalued opportunity,

 

Research and find more biotech stocks at Investorideas.com

https://www.investorideas.com/BIS/Stock_List.asp

About Investorideas.com

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for sectors including mining, crypto, renewable energy, gaming, biotech, tech, sports and more.

 

Disclaimer/Disclosure: This news article featuring Citius Pharmaceuticals, Inc. (CTXR) a paid for news release creation and dissemination on Investorideas.com.  Our site does not make recommendations for purchases or sale of stocks, services or products.  This is not investment opinion: Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services and prices on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ Global investors must adhere to regulations of each country. Privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Follow us on X @investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

 

Contact Investorideas.com

800-665-0411

 Biotech Industry Stocks- investing ideas in biotechnology stocks, medical technology and life sciences

Get more biotech and medical tech news, articles, podcasts and stock directories